Navigation Links
Ironwood and Forest to Present Additional Phase 2b Data for Novel Gastrointestinal Agent Linaclotide
Date:5/12/2009

Jeffrey Johnston, M.D., F.A.C.P., F.A.C.G. on Tuesday, June 2 from 8:00 a.m. to 5:00 p.m.

About Linaclotide

Linaclotide is a first-in-class compound in Phase 3 clinical development for the treatment of IBS-C and CC. Linaclotide demonstrated proof of concept in a comprehensive Phase 2b program, comprised of two clinical studies in over 700 patients with either IBS-C or CC. In patients with IBS-C, linaclotide significantly reduced abdominal pain and bloating and improved bowel function throughout the 12-week treatment period. In patients with CC, linaclotide reduced constipation throughout the 4-week treatment period. Across both studies, the most common adverse event in the linaclotide-treated groups was diarrhea. The discontinuation rate due to any adverse event was 4.7 percent. Linaclotide is a once daily, orally delivered peptide that acts locally in the gut with no detectable systemic exposure at therapeutic doses. Linaclotide is an agonist of guanylate cyclase type-C, a receptor found on the lining of the intestine. An issued composition of matter patent for linaclotide provides protection to 2025. In September 2007, Ironwood and Forest entered into a 50/50 collaboration to co-develop and co-promote linaclotide in United States.

About Irritable Bowel Syndrome with Constipation (IBS-C)

IBS-C is a chronic functional gastrointestinal disorder characterized by abdominal pain and discomfort associated with altered bowel habits. There are currently few available therapies to treat this disorder. Nine million U.S. patients have been diagnosed with IBS-C, and as many as 15 million people in the U.S. suffer from it. Patients suffering from IBS-C can be affected physically, psychologically, socially, and economically.

About Chronic Constipation (CC)

As many as 23 million Americans suffer from CC and 12 million patien
'/>"/>

SOURCE Forest Laboratories, Inc.; Ironwood Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Video: NASONEX(R) (Mometasone Furoate Monohydrate) Nasal Spray, 50 mcg* Teams Up With American Forests to Educate Nasal Allergy Sufferers and Help Improve Air Quality
2. Forest Laboratories, Inc. Reports Fiscal Year 2009 Fourth Quarter Reported EPS of $0.31 Including $0.45 Per Share Charge Related to the Ongoing United States Attorneys Office Investigation
3. AUDIO from Medialink and Forest Pharmaceuticals: FDA Approves Lexapro for Major Depressive Disorder in Adolescents
4. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Commercial Availability of Savella(TM)
5. AUDIO from Medialink and Forest Pharmaceuticals: FDA Approves Lexapro for Major Depressive Disorder in Adolescents
6. Forest Laboratories, Inc. Announces FDA Approval of Lexapro(R) for the Treatment of Major Depressive Disorder in Adolescents
7. German Federal Patent Court Invalidates Wake Forest NPWT Patents Licensed to KCI
8. Wake Forest Baptist and Rivulet Connect New Operating Rooms with Interactive Video
9. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Revised Timing for Commercial Availability of Savella(TM)
10. Forest Laboratories, Inc. Provides Statement in Response to Complaint Filed by U.S. Government
11. United States Files Complaint Against Forest Laboratories for Allegedly Violating the False Claims Act
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... new research study published today in the Journal ... patients older than 50 years with moderate or severe ... , Researchers from the University of Melbourne randomly assigned ... pain to no acupuncture or sham or pretend laser ... with participants and acupuncturists blinded to laser and sham ...
(Date:10/1/2014)... Patients with increased inflammation, including those receiving ... risk of depression. For example, a 6-month treatment ... virus infection causes depression in approximately 30% of ... known as fish oil, have a long list ... heart disease and reducing triglyceride levels. These nutritional ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Familylifeinsurancequotes.org ... find life insurance for senior citizens. , Senior ... Agencies will now sell coverage to seniors who are ... can be purchased without taking a medical examination. , ... purchased online and senior clients can qualify. Having life ...
(Date:10/1/2014)... Bedros Keuilian is not only the ... boot camps, he’s also considered the leading expert on ... out business summits, a line of high-demand fitness marketing ... recent Spike TV reality show to his name. , ... time for personal trainers and fitness business owners to ...
(Date:10/1/2014)... Oregon (PRWEB) October 01, 2014 Phoseon ... solutions , continues to expand the business worldwide. This ... along with additional capacity for manufacturing efforts. The company ... the last five years and expects this growth to ... LED curing technology gains worldwide adoption. , “We ...
Breaking Medicine News(10 mins):Health News:Study finds acupuncture does not improve chronic knee pain 2Health News:Omega-3 fatty acids may prevent some forms of depression 2Health News:Affordable Term Life Insurance - Senior Citizens Can Qualify for Coverage! 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 3Health News:Phoseon Technology Continues to Drive Growth Worldwide 2
... Finn, Jr., C.P.A. ("Finn") announced today that he has ... Brussels Branch. The statement is quoted in its entirety ... is a carbohydrate molecule which inhibits the activity of Galectin-3, ... of human cancers. Prospect reported that GCS-100 could induce ...
... studies show, , FRIDAY, June 5 (HealthDay News) -- One ... often not that interesting. But what if you could dance ... studies suggest that you just might be able to do ... Medicine meeting in Seattle, one study found that salsa dancing ...
... health centres and 680 pharmacies in the region are ready ... June 5 The Extremadura Regional Government of Spain and ... prescription system in 680 pharmacies in Extremadura, where health centres ... dispense prescription medications electronically. , , (Logo: ...
... who undergo myocardial infarction are experiencing onerous fatigue four months ... those who perceive the infarction as a sign of chronic ... and those who believe that the illness has a large ... thesis presented at the Sahlgrenska Academy, University of Gothenburg, Sweden. ...
... , MENTOR, Ohio, June 5 Join STERIS Isomedix Services ... critical to success in medical device sterilization ... 23, will provide attendees the opportunity to learn about sterilization ... , In addition to the TechTeam experts from STERIS Isomedix ...
... Ostomy Care Nurses Now Available Online , , ... and marketer of innovative medical technologies for community and ... (TM), an online, interactive community and resource. ... ostomy healthcare providers and will be unveiled at the ...
Cached Medicine News:Health News:Ludwig Institute of Cancer Research Ltd., Brussels Branch, Issues Statement Concerning Prospect Therapeutics Inc's. GCS-100 Molecule 2Health News:Finding Fitness on the Dance Floor 2Health News:Finding Fitness on the Dance Floor 3Health News:Spain's Regional Extremadura Government Launches Electronic Prescription System With IBM 2Health News:Fatigue common after myocardial infarction 2Health News:Medical Device Sterilization Seminar Offered by STERIS Isomedix Services 2Health News:Medical Device Sterilization Seminar Offered by STERIS Isomedix Services 3Health News:ConvaTec Launches New Programs to Support and Recognize WOC Nursing 2Health News:ConvaTec Launches New Programs to Support and Recognize WOC Nursing 3
(Date:10/2/2014)... 1, 2014 The global high content screening ... the ,Threat of Obsolescence, wherein technologies as well as ... and biotechnology companies as well as academic and government ... as a powerful research tool in drug discovery. The ... in the high content screening market. In high content ...
(Date:10/1/2014)... Oct. 1, 2014  Dyadic International, Inc. ("Dyadic") ... and proprietary technology used to develop and produce ... chemicals, biopharmaceuticals, and industrial enzymes industries, today announced ... Abengoa Bioenergy for commercial scale production of Abengoa,s ... ethanol, developed under Abengoa,s license agreement with Dyadic. ...
(Date:10/1/2014)... 1, 2014 Trovagene, Inc., (NASDAQ:  TROV) ... that Eli Diamond , MD, Assistant Attending ... presented clinical data from an ongoing study demonstrating ... for the determination of oncogene mutational status in ... results were presented to both treating physicians and ...
Breaking Medicine Technology:High Content Screening Market by Instruments (Cell Imaging and Analysis System), by Applications (Primary and Secondary Screening, Target Identification and Validation, Toxicity Studies, Compound Profiling), Software & Services - Global Forecasts to 2High Content Screening Market by Instruments (Cell Imaging and Analysis System), by Applications (Primary and Secondary Screening, Target Identification and Validation, Toxicity Studies, Compound Profiling), Software & Services - Global Forecasts to 3Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 2Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 3Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 2Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 3Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 4
... The Leukemia & Lymphoma,Society has awarded a $550,000 grant ... Cancer Center at the University of Rochester Medical,Center. Millennium ... the first two years of the five-year program., ... support,Dr. Friedberg,s work on a new targeted treatment for ...
... Medivation, Inc.,(Nasdaq: MDVN ) today announced that ... on Monday, July 7, to discuss top-line results ... of,dimebon(TM) in Huntington,s disease., Teleconference/Webcast Details, ... July 7, at 5:00 p.m. Eastern,time by telephone, ...
Cached Medicine Technology:University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society 2Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntington's Disease 2
... PACHETT 3 uses the exact enhanced corneal ... DGH pachymeters used exclusively by the OHTS ... into the software. The new backlit LCD ... average, standard deviation and IOP correction calculation ...
The Medmont C100 Colour Vision Tester is an electronic colour vision screening device which is used to rapidly detect red/green colour vision deficiencies. Its high sensitivity provides a positive in...
... E300 Corneal Topographer has applications ... clinical procedures including Radial Keratotomy, ... Contact Lens Fitting. Based on ... the E300 analyses an accurate ...
... first Open Bore MR ,Siemens has combined, for ... bore, a very short 125 cm magnet and ... very revolutionary: Open Bore MR. And MAGNETOM Espree, ... A unique Siemens technology, which means faster, more ...
Medicine Products: